Talaris Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update

BOSTON and LOUISVILLE, Ky., June 14, 2021 (GLOBE NEWSWIRE) — Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today